TerminatedPhase 2ACTRN12609000708257

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

A Randomized Open Label Study Comparing the Efficacy, Safety and Tolerability of Oral Administration of Amantadine and Ribavirin and Oseltamivir Versus Oseltamivir to Influenza A Virus Infected Immunocompromised Subjects.

Sponsor

Adamas Pharmaceuticals, Inc

Enrollment

125 participants

Start Date

Aug 1, 2009

Study Type

Interventional

Conditions

Immune compromised Influenza A

Summary

The primary purpose of this study is to examine the effect of triple combination anti viral drug (TCAD) in influenza infection in immunocompromised subjects. TCAD may potentially produce a greater reduction in viral load in these subjects and potentially block drug resistance therefore reducing morbidity in influenza A infection in immunocompromised subjects.

Eligibility

Sex: Both males and femalesMin Age: 1 YearsMax Age: 65 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests a combination of three antiviral drugs to treat influenza A (the flu) in people with weakened immune systems, such as organ transplant recipients, people on chemotherapy, or those with HIV. Participants must be aged 1 to 65 and have had flu symptoms for no more than 3 days.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Amantadine treatment for 10 days, Ribavirin treatment for 10 days and Oseltamivir treatment for 10 days. Potential subjects will be advised of treatment schedule and dosage at time of consent.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12609000708257